A Two-Step Reevaluation of High-Dose Amsacrin for Advanced Carcinoma of the Upper Aerodigestive Tract: A pilot phase II study

References

• Arlin ZA, Geet S, Mertelsmann R. Randomised trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside (ARA-C) and thioguanin (TG) vs. Daunorubicin with ARA-C and TG in adults with acute non-lymphoblastic leukemia (ANLL). Ed. Proc. Int. Symposium Amsacrine. Current perspectives and clinical results with a new anti-cancer agent. New Jersy, USA. Comunication Media for Education Inc. 1983: 77.
   Google Scholar
• Hines JD, Oken MM, Mazza J, Keller A, Streeter R. High dose cytosine arabinoside (ARA-C) and M-AMSA in relapsed acute non-lymphocytic leukemia (ANLL). ASCO abstracts 1983; 2: 173 (Abs. C-672).
   Google Scholar
• Woodcock TM, Schneider RJ, Young CW. Phase I eval-uation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly i.v. dose schedule. Cancer Treat Rep 1980; 64: 53–55.
   PubMedGoogle Scholar
• Van Echo DA, Chuiten DG, Gormley P, Lichtenfeld JL, Scoltock M, Wiemick PH. Phase I clinical and pharmacologi-cal study of 4'-(9-acridinylamino) methanesulfon-m-anisidide using an intermittent bi-weekly schedule. Cancer Res 1979; 39: 3381-3384.
   Google Scholar
• Von Hoff DD, Howser D, Gormley P, et al. Phase I study of methanesulfonamide N44-(9-acridinylamino)-3-methoxyphenyll- (M-AMSA) using a single-dose schedule. Cancer Treat Rep 1978; 62; 1421-1426.
   Google Scholar
• De Jager R, Siegenthaler P, Dombernowsky P, et al. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-ani-sidide (M-AMSA, NSC 249992). Proc Am Assoc Cancer Res 1981; 22: 367 (Abs. C-139).
   Google Scholar
• Murphy WK, Valdivieso M, Legha SS, Bodey GP. A phase II study of 4'-(9-acridinylamino)methanesulfon-m-ani-sidide (AMSA) in patients with metastatic lung cancer. Proc Am Assoc Cancer Res 1980; 21: 456 (Abs. C-542).
   Google Scholar
• Lessner HE, Kaplan RS. M-AMSA treatment of advanced colorectal (Co), pancratic (Pa), and gastric (Ga) carcinoma. Proc Am Assoc Cancer Res 1981; 22: 454 (Abs. C-474).
   Google Scholar
• Goldsmith MA, Bhardwaj S, Ohnuma T, Greenspan EM, Holland JF. Phase I study of M-AMSA in patients with solid tumors and leukemias. Cancer Chin Trials 1980; 3: 197–202.
   PubMed Web of Science ®Google Scholar
• Legha SS, Gutterman JU, Hall SW, et al. Phase I dini-cal investigation of 4'-(9-acridinylamino)methanesulfon-m-ani-sidide (NSC 249992), a new acridine derivative. Cancer Res 1978; 38: 3712-3716.
   Google Scholar
• Schneider R, Sklaroff R, Ochoa M, Young C. Phase I trial of AMSA. Proc Am Assoc Cancer Res 1979; 20: 114 (Abs. 461).
   Google Scholar
• Woodcock TM, Schneider RJ, Young CW. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly i.v. dose schedule. Cancer Treat Rep 1980; 64: 53–55.
   PubMedGoogle Scholar
• Milles AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207–214.
   PubMed Web of Science ®Google Scholar
• Zander A, Spitzer G, Legha S, et al. High dose AMSA and autologous bone marrow transplantation (ABMT) in patients with solid tumors. Proc Am Assoc Cancer Res 1981; 22: 929.
   Google Scholar
• Tannir N, Spitzer G, Legha S, Zander A, Blumenshein G. Phase II study of high dose amsacrine (AMSA) and autol-ogous bone marrow transplantation in patients with refracto-ry metastatic breast cancer. Cancer Treat Rep 1983; 67: 599–600.
   PubMedGoogle Scholar
• Zittoun R. M-AMSA: A review of clinical data. Eur J Cancer Clin Oncol 1985; 21: 649–665.
   PubMedGoogle Scholar
• Yagoda A. Chemotherapy for urothelial tract cancer. Cancer Invest 1986; 4 (5): 20–26.
   Google Scholar
• Al-Sarraf M, Frank J, Smith JA, et al. Phase II trial of cyclophosphamide, doxorubicin and cisplatin (CAP) vs. amsacrine in patients with transitional cell carcinoma of the urinary bladder: A Southwest Oncology Group Study. Cancer Treat Rep 1985; 69 (2): 189–194.
   Google Scholar
• Crivellari D, Tirelli U, Frustaci S, et al. A phase II study of AMSA in head and neck cancer. Am J Clin Oncol (CCT) 1987; 10 (1): 23–25.
   PubMed Web of Science ®Google Scholar
• Forestiere AA, Young CW, Witter RE. A phase II trial of m-AMSA in head and neck cancer. Cancer Chemother Pharmacol 1981; 6: 145–146.
   PubMed Web of Science ®Google Scholar
• Ratanatharathom V, Drelichman A, Sexon-Porte M, Al-Sarraf M. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with advanced head and neck cancers. Am J Clin Oncol (CCT) 1982; 5: 29–32.
   PubMed Web of Science ®Google Scholar
• Larsson R, Nygren P. Cytotoxic activity of topoisomerase II inhibitors in primary cultures of tumor cells from patients with human hematologic and solid tumors. Cancer, 1994; 74 (10): 2857–2862.
   PubMed Web of Science ®Google Scholar
• Nitiss JL, Vilalta PM, Wu H, McMahon J. Mutations in the gyrb domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Mol Pharmacol 1994; 46 (4): 773–777.
   PubMed Web of Science ®Google Scholar
• Finley GJ. Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells. Cancer Chemother Pharmacol 1994; 34 (2): 159–165.
   PubMed Web of Science ®Google Scholar
• Cornford EM, Young D, Paxton JW. Comparison of the blood-brain barrier and liver penetration of acridine anti-tumor drugs. Cancer Chemother Pharmacol 1992; 29 (6): 439–444.
   PubMed Web of Science ®Google Scholar
• Sorbe BG, Hogberg T, Glimelius B, Schmidt M, Wemstedt L. A randomized, multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis. Cancer 1994; 73 (2): 445–454.
   PubMed Web of Science ®Google Scholar
• Catimel G, Chauvin F, Biron P, Clavel M. Multivariate analysis of prognostic factors influencing emesis for patients undergoing cisplatin-based chemotherapy. Proc Annu Meet Am Soc Clin Oncol 1991; 10: A1210.
   Google Scholar
• Dreyfus F, Leblond V, Belanger C, Gabarre J, Sutton L. Peripheral blood stem cell collection and autografting in high risk lymphomas. Bone Marrow Transplant 1992; 10 (5): 4090–413.
   Google Scholar
• Eton 0, Legha S, Papadopoulos N, Plager C, Ring S. Long-term survival in patients with metastatic melanoma at MD Anderson Cancer Center. Proc Annu Meet Am Soc Clin Oncol 1992; 11: A1183.
   Google Scholar
• Carugati A, Olivari A, Pradier R. Six-year follow-up of stages III and IV (MO) head and neck cancer patients with chemotherapy pre-radical treatment. Proc Annu Meet Am Soc Clin Oncol, 1985; 4: 153.
   Google Scholar
• Wittes R, Heller K, Randolph V. Cis-dichlorodi-amminoplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep 1979; 63: 1533–1538.
   PubMedGoogle Scholar
• Basauri LA, Pousa AL, Alba E, Sampedro F. Carboplatin, an active drug in advanced head and neck can-cer. Cancer Treat Rep 1986; 70: 1173–1176.
   PubMedGoogle Scholar